

What is claimed is

1 1. A humanized immunoglobulin, which is a humanized
2 version of the mouse AF2 immunoglobulin having a light chain
3 variable region designated SEQ ID No:2 and a heavy chain
4 variable region designated SEQ ID No:4, the humanized
5 immunoglobulin comprising humanized heavy and light chains,
6 provided that position 11 of the humanized heavy chain
7 variable region framework is occupied by the amino acid
8 present in the equivalent position of the mouse AF2 heavy
9 chain variable region framework.

1 2. The humanized immunoglobulin of claim 1,
2 comprising CDRs from the mouse AF2 immunoglobulin and heavy
3 and light chain variable region frameworks from the human EU
4 immunoglobulin.

1 3. The humanized immunoglobulin of claim 2, further
2 provided that position H38 is occupied by the amino acid
3 present in the equivalent position of the mouse AF2 heavy
4 chain variable region framework.

1 4. The humanized immunoglobulin of claim 2, further
2 provided that positions H11, H27, H28, H30, H38, H48, H67,
3 H68, H70, H72, H74, H93, H95, H98, H107, H108, H109, H111 are
4 occupied by the amino acid present in the equivalent position
5 of the mouse AF2 heavy chain, positions L48, and L70 are
6 occupied by the amino acid present in the equivalent position
7 of the mouse AF2 light chain, and position L63 is occupied by
8 the amino acid present in the equivalent position of a
9 consensus sequence of light chains of human immunoglobulins.

1 5. The humanized immunoglobulin of claim 1 that
2 specifically binds to human γ -IFN with an affinity constant
3 within four-fold of the affinity of the mouse AF2 antibody.

1 6. The humanized immunoglobulin of claim 1 that
2 specifically binds to γ -IFN comprising a humanized mature light

chain having at least 90% sequence identity to the mature light chain of SEQ ID No:6, and a humanized mature heavy chain having at least 90% sequence identity to the mature heavy chain of SEQ ID No:8.

7. The humanized immunoglobulin according to claim 1 that comprises two light chain/heavy chain dimers.

8. The humanized immunoglobulin of claim 1 that is of IgG1 isotype.

9. The humanized immunoglobulin according to claim 1, which is purified to at least 95% homogeneity.

10. A humanized immunoglobulin comprising a mature heavy chain variable region designated SEQ ID No:6 and a mature light chain variable region designated SEQ ID No:8.

11. A pharmaceutical composition comprising a humanized immunoglobulin of claim 1 or 10 and a pharmaceutically acceptable carrier.

12. A method of treating a patient suffering from a harmful immune response, comprising administering a therapeutically effective dosage of the pharmaceutical composition of claim 1 or 10.

13. The method of claim 12, wherein the patient is suffering from an autoimmune disease.